Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.

@article{Syed2011PololikeKP,
  title={Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.},
  author={Nelofer Syed and Helen M. Coley and Jalid Sehouli and Dominique Koensgen and Alexander Mustea and Peter Wojciech Szlosarek and Iain A McNeish and Sarah P. Blagden and Peter Schmid and David Paul Lovell and Eleftheria Hatzimichael and Tim Crook},
  journal={Cancer research},
  year={2011},
  volume={71 9},
  pages={3317-27}
}
Resistance to platinum- and taxane-based chemotherapy remains a major clinical impediment to effective management of epithelial ovarian cancer (EOC). To gain insights into resistance mechanisms, we compared gene and confirmed expression patterns of novel EOC cell lines selected for paclitaxel and carboplatin resistance. Here, we report that resistance can be conferred by downregulation of the Polo-like kinase Plk2. Mechanistic investigations revealed that downregulation occurred at the level of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high - density oligonucleotide microarrays

  • YooBC JuW, IJ Kim, JW Kim, SC Kim, LeeHP
  • Oncol Rep
  • 2009

Similar Papers

Loading similar papers…